Will Medicare cover Zepbound and other weight loss drugs in 2026?
Answered by 3 licensed agents
Beginning July 1, 2026, Medicare will make certain Glp-1 medications available to eligible Medicare Part D policyholders for the treatment of obesity and weight loss under the Bridge Program. This is a temporary in that will run through December 31, 2027.
Medicare will manage this program. This is separate from the Medicare Beneficiary’s Medicare Part D coverage.
Source: Anthem BC/BS Medicare.
Plans are insured or covered by a Medicare Advantage (HMO, PPO and PFFS) organization with a Medicare contract and/or a Medicare-approved Part D sponsor. Enrollment in the plan depends on the plan’s contract renewal with Medicare. We do not offer every plan available in your area. Any information we provide is limited to those plans we do offer in your area. Please contact Medicare to get information on all of your options.
Answered by Andrew Zurbuch, MBA on June 24, 2026
Broker Licensed in IN, FL, KY, MO, OH & TN
Answered by Rich Baker on June 24, 2026
Broker Licensed in CO, AR, AZ & 9 other states
Starting July 1, 2026, Medicare is expected to provide access to certain GLP-1 weight loss drugs through what is called the Medicare GLP-1 Bridge program. This would apply to eligible people who have Medicare Part D coverage.
The drugs currently listed under this program include Foundayo, Wegovy, and Zepbound. For Zepbound, Medicare specifically lists the Zepbound KwikPen, not the single-dose vials or pens.
This is also a temporary program. It is scheduled to run from July 1, 2026 through December 31, 2027. One important detail is that this program operates outside the normal Part D payment system, which means Part D plans do not have to opt in for eligible beneficiaries to access the program.
The expected cost is a $50 copay for a one-month supply. However, that $50 does not count toward the Part D deductible or the annual out-of-pocket limit, and it cannot be reduced by Extra Help or LIS.
The biggest thing to understand is that eligibility is not simply based on wanting to lose weight. A provider would need to submit a prior authorization, and the patient would need to meet certain clinical requirements.
Those requirements may include BMI levels along with specific health conditions. For example, someone may qualify based on a BMI of 35 or higher, a BMI of 30 or higher with certain conditions such as heart failure, uncontrolled hypertension, or chronic kidney disease, or a BMI of 27 or higher with conditions such as prediabetes, a prior heart attack, prior stroke, or peripheral artery disease.
It is also important to separate weight loss coverage from coverage for another medical diagnosis. If a GLP-1 medication is prescribed for a Medicare-coverable diagnosis, such as Type 2 diabetes, obstructive sleep apnea, or MASH, that would generally be reviewed through the person’s regular Part D plan, not the GLP-1 Bridge program.
So the short answer is yes, but not for everyone.
Answered by Matt Maresch on June 24, 2026
Agent Licensed in TX
Tags: Coverage Medicare Part D Prescription Drug
Agents: Share Your Expertise
Have insights or experiences related to this topic? Help others by sharing your knowledge and answering this question.
Seniors: Ask a Question of Your Own
Questions are generally answered within 1 to 3 business days. Receive valuable perspectives from multiple licensed agents and brokers.
Ask a Question